rna helicase

Werner syndrome RecQ helicase-IN-1 is a potent Werne r syndrome RecQ DNA deconjugase (WRN) inhibitor that can be used to study cancers such as colon and stomach cancer.

ML216 (CID-49852229) is a small molecule inhibitor of BLM helicase with an IC50 of 1.8 μM, demonstrating 28-fold selectivity against the related helicases RECQ1, RECQ5, and E. coli UvrD (IC50s > 50 μM).

Brr2-IN-3 (Brr2 Inhibitor C9) is an allosteric inhibitor of the spliceosomal RNA helicase Brr2. Brr2 is implicated in autosomal-dominant retinitis pigmentosa (a group of progressive retinal degenerative disorders).

NCGC00029283 is a potent inhibitor of Werner syndrome helicase-nuclease (WRN), displaying inhibitory activity against WRN helicase with an IC 50 value of 2.3 μM. Additionally, it exhibits inhibitory effects on Bloom syndrome protein helicase (BLM) and Fanconi anemia group J protein helicase (FANCJ) with IC 50 values of 12.5 μM and 3.4 μM, respectively.

CMLD012073 is a potent eukaryotic initiation factor 4A (eIF4A) inhibitor. It inhibits NIH 3T3 cells (IC50: 10 nM). CMLD012073 inhibits eukaryotic translation initiation by modifying the behavior of the RNA helicase (eIF4A).

Supinoxin (RX-5902) is an orally active inhibitor of phosphorylated-p68 RNA helicase and a potent first-in-class anti-cancer agent, inducing cell apoptosis and inhibiting the growth of TNBC cancer cell lines (IC50s: 10 nM - 20 nM).

GBM CSCs-IN-1 (Compound (−)-20), a rocaglate derivative, potently inhibits glioblastoma stem cells (GBM CSCs) and exhibits an EC50 of 45 nM by targeting the RNA helicase DDX3. Additionally, it induces apoptosis in these cells.

YK 4-279, an inhibitor of RNA Helicase A (RHA), binds to the oncogenic transciption factor EWS-FLI1.

MIRA-1 (WRN Helicase Inhibitor) is a restorer of wild-type p53 conformation cellular function and selectively inhibits Werner syndrome WRN helicase activity with an IC50 of 20 µM.

Pritelivir (BAY 57-1293) (BAY 57-1293) is a potent helicase-primase inhibitor with active against HSV-1 and HSV-2 (IC50: 20 nM).

Amenamevir (ASP2151) is a novel helicase-primase inhibitor that is active against varicella-zoster virus and herpes simplex virus types 1 and 2 (EC50: 14 ng mL).

RK33 (RK 33) is a first-in-class small molecule inhibitor of DDX3 (a RNA helicase) and causes G1 cell cycle arrest, induces apoptosis, and promotes radiation sensitization in DDX3-overexpressing cells.

DHX9-IN-2 is an inhibitor targeting ATP-dependent RNA de-helicase A (DHX9) with anticancer and antitumor activity for cancer research.

DHX9-IN-1 is a potent ATP-dependent RNA helicase A (DHX9) inhibitor, exhibiting an IC50 of 9.45 nM and demonstrating antitumor activity [1].

DHX9-IN-10 (49) serves as an inhibitor of the RNA helicase DHX9, exhibiting an EC50 of 9.04 μM for DHX9 cellular target engagement. It is primarily utilized in cancer research [1].

DHX9-IN-11 (469) serves as an inhibitor of the RNA helicase DHX9, exhibiting an EC 50 value of 0.0838 μM in assays measuring cellular target engagement. This compound is utilized in cancer research [1].

DHX9-IN-12 (83) serves as an inhibitor of the RNA helicase DHX9, exhibiting an EC 50 of 0.917 μM for DHX9 cellular target engagement. It is utilized in the field of cancer research [1].

DHX9-IN-13 (389) serves as an inhibitor of the RNA helicase DHX9, demonstrating a cellular target engagement EC50 of 3.4 μM. It is primarily utilized in cancer research [1].

DHX9-IN-14 (161), an RNA helicase DHX9 inhibitor, has an EC50 of 3.4 μM in DHX9 cellular target engagement and is utilized in cancer research [1].

DHX9-IN-15 (287) functions as an inhibitor of the RNA helicase DHX9, exhibiting cellular target engagement with an EC50 of 0.232 μM. It is primarily utilized in cancer research [1].

DHX9-IN-16 (208) acts as an inhibitor of the RNA helicase DHX9, exhibiting an EC 50 value of 0.125 μM for DHX9 cellular target engagement. It is utilized in cancer research [1].

DHX9-IN-17 (186) serves as an inhibitor of the RNA helicase DHX9, demonstrating a target engagement EC50 value of 0.161 μM in cellular assays. It is utilized in cancer research [1].

DHX9-IN-3 (Compound 621) acts as an ATP-dependent inhibitor of RNA helicase A (DHX9), and holds potential for use in cancer research [1].

DHX9-IN-4 is an ATP-dependent RNA helicase DHX9 inhibitor used in cancer research.